Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults.

Singleton RJ, Butler JC, Bulkow LR, Hurlburt D, O'Brien KL, Doan W, Parkinson AJ, Hennessy TW.

Vaccine. 2007 Mar 8;25(12):2288-95. Epub 2006 Dec 11.

PMID:
17254673
2.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

3.

Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005.

Bliss SJ, Larzalere-Hinton F, Lacapa R, Eagle KR, Frizzell F, Parkinson A, Reid R, Craig M, Santosham M, O'Brien KL.

Arch Intern Med. 2008 Apr 14;168(7):749-55. doi: 10.1001/archinte.168.7.749.

PMID:
18413558
4.

The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990--ethnic differences and opportunities for prevention.

Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ.

J Infect Dis. 1994 Aug;170(2):368-76.

PMID:
8035023
5.

Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply.

Wenger JD, Zulz T, Bruden D, Singleton R, Bruce MG, Bulkow L, Parks D, Rudolph K, Hurlburt D, Ritter T, Klejka J, Hennessy T.

Pediatr Infect Dis J. 2010 Mar;29(3):251-6. doi: 10.1097/INF.0b013e3181bdbed5.

PMID:
19952861
6.

Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.

Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J; Massachusetts Department of Public Health Epidemiologists.

Pediatr Infect Dis J. 2005 Jan;24(1):17-23.

PMID:
15665705
7.

Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults.

Benin AL, O'Brien KL, Watt JP, Reid R, Zell ER, Katz S, Donaldson C, Parkinson A, Schuchat A, Santosham M, Whitney CG.

J Infect Dis. 2003 Jul 1;188(1):81-9. Epub 2003 Jun 23.

8.

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.

Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.

Pediatr Infect Dis J. 2007 Sep;26(9):771-7.

PMID:
17721369
9.

Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.

Bruce MG, Singleton R, Bulkow L, Rudolph K, Zulz T, Gounder P, Hurlburt D, Bruden D, Hennessy T.

Vaccine. 2015 Sep 11;33(38):4813-9. doi: 10.1016/j.vaccine.2015.07.080. Epub 2015 Aug 4.

10.

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004.

Mooney JD, Weir A, McMenamin J, Ritchie LD, Macfarlane TV, Simpson CR, Ahmed S, Robertson C, Clarke SC.

BMC Infect Dis. 2008 Apr 23;8:53. doi: 10.1186/1471-2334-8-53.

11.

Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.

Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW.

Clin Infect Dis. 2009 Jul 15;49(2):205-12. doi: 10.1086/599827.

12.

The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations.

Said MA, O'Brien KL, Nuorti JP, Singleton R, Whitney CG, Hennessy TW.

Vaccine. 2011 Jul 26;29(33):5355-62. doi: 10.1016/j.vaccine.2011.05.086. Epub 2011 Jun 12.

PMID:
21664217
13.

Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006.

Motlova J, Benes C, Kriz P.

Epidemiol Infect. 2009 Apr;137(4):562-9. doi: 10.1017/S0950268808001301. Epub 2008 Sep 16.

PMID:
18796171
14.

Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003.

Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili T, Roberson A, Zell ER, Whitney CG, Bennett NM; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.

Clin Infect Dis. 2006 Jul 15;43(2):141-50. Epub 2006 Jun 9.

15.

Invasive pneumococcal disease in an underimmunized, high HIV prevalence population.

Tasslimi A, Wenger P, Pentakota SR, Brimacombe M, Burday M, Sinha A.

J Infect. 2008 Feb;56(2):99-102. doi: 10.1016/j.jinf.2007.11.005. Epub 2008 Jan 10.

PMID:
18190966
16.

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.

Andrews NJ, Waight PA, George RC, Slack MP, Miller E.

Vaccine. 2012 Nov 6;30(48):6802-8. doi: 10.1016/j.vaccine.2012.09.019. Epub 2012 Sep 18.

PMID:
23000122
17.

Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England.

Foster D, Knox K, Walker AS, Griffiths DT, Moore H, Haworth E, Peto T, Brueggemann AB, Crook DW; Oxford Invasive Pneumococcal Surveillance Group.

J Med Microbiol. 2008 Apr;57(Pt 4):480-7. doi: 10.1099/jmm.0.47690-0.

PMID:
18349369
18.

Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine.

Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR.

Clin Infect Dis. 2004 Sep 1;39(5):641-8. Epub 2004 Aug 16.

19.

Immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in Alaska Native chronic alcoholics compared with nonalcoholic Native and non-Native controls.

McMahon BJ, Parkinson AJ, Bulkow L, Davidson M, Wainwright K, Wolfe P, Schiffman GS.

Am J Med. 1993 Dec;95(6):589-94.

PMID:
8259775
20.

Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk